License

License Not Specified

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

A Phase II Multi-Dose Study of SGN-30 anti-CD30 mAb in Patients with Refractory or Recurrent Hodgkins Disease or Anaplastic Large Cell Lymphoma

The primary objectives of this phase II study are as follows: - To determine the objective response rate of SGN-30 in two study groups patients with HD treated with 6 or 12 mgkg and patients with ALCL treated with 6 or 12 mgkg - To determine the duration of response in patients with HD and in patients with ALCL - To investigate the toxicity profile of SGN-30 at a dose of 6 or 12 mgkg for ALCL or doses of 6 or 12 mgkg for HD

FieldValue
Modified
2020-02-24
Release Date
2019-05-09
Identifier
04da2b61-4e44-459e-ab6f-174bdf4adae4
License
License Not Specified
Public Access Level
Public